DOP2023000194A - Moduladores de sting (estimulador de genes de interferón) - Google Patents

Moduladores de sting (estimulador de genes de interferón)

Info

Publication number
DOP2023000194A
DOP2023000194A DO2023000194A DO2023000194A DOP2023000194A DO P2023000194 A DOP2023000194 A DO P2023000194A DO 2023000194 A DO2023000194 A DO 2023000194A DO 2023000194 A DO2023000194 A DO 2023000194A DO P2023000194 A DOP2023000194 A DO P2023000194A
Authority
DO
Dominican Republic
Prior art keywords
stimulator
interferon genes
sting modulators
compounds
sting
Prior art date
Application number
DO2023000194A
Other languages
English (en)
Inventor
James Wythes Martin
Yuanjin Rui Eugene
Jalaie Mehran
Satish Gajiwala Ketan
Woo HUH Chan
Sun Jianmin
Lloyd Patman Ryan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2023000194A publication Critical patent/DOP2023000194A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente se proporcionan compuestos de la Fórmula general (I): , y sales aceptables desde el punto de vista farmacéutico de estos, procesos para la preparación de estos compuestos, composiciones que contienen estos compuestos y los usos de estos compuestos.
DO2023000194A 2021-03-18 2023-09-14 Moduladores de sting (estimulador de genes de interferón) DOP2023000194A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162640P 2021-03-18 2021-03-18
US202163165459P 2021-03-24 2021-03-24
PCT/IB2022/052300 WO2022195462A1 (en) 2021-03-18 2022-03-15 Modulators of sting (stimulator of interferon genes)

Publications (1)

Publication Number Publication Date
DOP2023000194A true DOP2023000194A (es) 2023-11-30

Family

ID=80819922

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000194A DOP2023000194A (es) 2021-03-18 2023-09-14 Moduladores de sting (estimulador de genes de interferón)

Country Status (17)

Country Link
US (1) US11964978B2 (es)
EP (1) EP4308563A1 (es)
JP (1) JP2024509982A (es)
KR (1) KR20230146606A (es)
AU (1) AU2022238001A1 (es)
BR (1) BR112023017731A2 (es)
CA (1) CA3213427A1 (es)
CL (1) CL2023002737A1 (es)
CO (1) CO2023012198A2 (es)
CR (1) CR20230413A (es)
DO (1) DOP2023000194A (es)
EC (1) ECSP23070418A (es)
IL (1) IL306034A (es)
MX (1) MX2023010942A (es)
TW (1) TWI829112B (es)
UY (1) UY39676A (es)
WO (1) WO2022195462A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222644A1 (en) 2022-05-18 2023-11-23 F. Hoffmann-La Roche Ag Pyrazole derivatives as sting agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP2432776B1 (en) 2009-05-21 2019-09-11 Universite Laval Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics
BR112013005699B1 (pt) 2010-09-09 2021-08-17 Pfizer Inc Anticorpo isolado ou porção de ligação ao antígeno do mesmo que se liga ao 4-1bb humano, combinação, usos dos mesmos, bem como composição farmacêutica, molécula de ácido nucleico isolada e vetor
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
MX2018008995A (es) 2016-01-25 2019-01-10 Pfizer Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
WO2017175156A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
CA3024482A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
CN111132972A (zh) * 2017-06-22 2020-05-08 克拉德夫制药有限公司 人sting的小分子调节剂
TWI741268B (zh) * 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑
WO2020028565A1 (en) * 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
EP3934652A4 (en) * 2019-03-05 2022-12-07 F-Star Therapeutics, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
CN114302875A (zh) * 2019-05-16 2022-04-08 斯汀塞拉股份有限公司 氧代吖啶基乙酸衍生物及使用方法
WO2021059136A1 (en) 2019-09-25 2021-04-01 Pfizer Inc. Polyheterocyclic modulators of sting (stimulator of interferon genes)

Also Published As

Publication number Publication date
JP2024509982A (ja) 2024-03-05
KR20230146606A (ko) 2023-10-19
TWI829112B (zh) 2024-01-11
AU2022238001A1 (en) 2023-09-14
BR112023017731A2 (pt) 2023-10-03
CR20230413A (es) 2023-10-13
UY39676A (es) 2022-10-31
WO2022195462A1 (en) 2022-09-22
TW202246262A (zh) 2022-12-01
CL2023002737A1 (es) 2024-04-01
MX2023010942A (es) 2023-09-28
CA3213427A1 (en) 2022-09-22
EP4308563A1 (en) 2024-01-24
US20220306641A1 (en) 2022-09-29
IL306034A (en) 2023-11-01
CO2023012198A2 (es) 2023-11-30
ECSP23070418A (es) 2023-10-31
US11964978B2 (en) 2024-04-23

Similar Documents

Publication Publication Date Title
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CL2018001484A1 (es) Dinucleotidas de purino ciclico como moduladores de estimulador de genes de interferon (sting).
CO2022008091A2 (es) Inhibidores de kras g12c
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
UY31063A1 (es) Derivados de n-[6-amino-5-aril-piridin -2-il]-carboxamida, composiciones conteniéndolos, procedimientos de preparación, itermedios utilizados en la preparación y aplicaciones.
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
ECSP23070418A (es) Moduladores de sting (estimulador de genes de interferón)
CO2022004723A2 (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2022003646A1 (es) Derivados de amidopirimidona
ECSP19066134A (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
CO2022001814A2 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CO2024002844A2 (es) Compuestos espirocíclicos
CO2023012903A2 (es) Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2)
ECSP18056196A (es) Derivados de indano
CL2004000630A1 (es) Compuestos derivados de oxazol; sales de dichos compuestos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que contiene dichos compuestos; y su uso para inhibir el crecimiento tumoral.
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)